|
|
|
|
| LEADER |
00000cam a2200000Mu 4500 |
| 001 |
on1057675628 |
| 003 |
OCoLC |
| 005 |
20241006213017.0 |
| 006 |
m o d |
| 007 |
cr |n|---||||| |
| 008 |
181020s2018 xx o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d YDX
|d OCLCQ
|d LOA
|d OCLCO
|d OCLCF
|d K6U
|d OCLCQ
|d OCLCO
|d OCLCL
|
| 066 |
|
|
|c (S
|
| 019 |
|
|
|a 1057234727
|
| 020 |
|
|
|a 9781681086071
|
| 020 |
|
|
|a 1681086077
|
| 035 |
|
|
|a (OCoLC)1057675628
|z (OCoLC)1057234727
|
| 050 |
|
4 |
|a RM301.4
|b .F766 2018
|
| 049 |
|
|
|a HCDD
|
| 100 |
1 |
|
|a Atta-ur-Rahman.
|
| 245 |
1 |
0 |
|a Frontiers in Clinical Drug Research - CNS and Neurological Disorders.
|
| 260 |
|
|
|a Sharjah :
|b Bentham Science Publishers,
|c 2018.
|
| 300 |
|
|
|a 1 online resource (218 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Frontiers in Clinical Drug Research - CNS and Neurological Disorders Ser. ;
|v v. 6
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|6 880-01
|a Intro; CONTENTS; PREFACE; List of Contributors; Depression, Insomnia and Atypical Antidepressants; Laura Betti1,*, Lionella Palego2 and Gino Giannaccini1; INTRODUCTION; Neurobiology of Sleep; Mammalian Sleep: Evolution and Architecture; Sleep and Mood; Sleep and Ageing; Subjective Evaluations of Sleep; INSOMNIA IN DEPRESSION; Major Depression; Seasonal Depression, Atypical Depression; Depression with Anxiety; Bipolar Disorder; TREATMENT OF INSOMNIA; ANTIDEPRESSANTS AND SLEEP; First Generation Antidepressants; Second Generation Antidepressants, SSRIs and SNRIs.
|
| 505 |
8 |
|
|a Selective Noradrenalin Reuptake Inhibitors (NARIs)Atypical Antidepressants; Trazodone and Melatonin; CONCLUSION; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGMENTS; REFERENCES; Combination Therapy of Hypothermia for Hypoxic Encephalopathy in Neonates; Renjith Kalikkot Thekkeveedu, Abhay Bhatt, Sumana Ramarao, Zhengwei Cai and Yi Pang*; INTRODUCTION: PERINATAL BRAIN INJURY AND TREATMENT; HYPOTHERMIA TREATMENT; The Evolvement of Hypothermia as a Neuroprotective Strategy; Mechanisms Underlying Neuroprotective Effects of TTM; Clinical Trials of TTM on HIE: Success and Limitation.
|
| 505 |
8 |
|
|a Clinical Trials that Reported Short-term EvaluationClinical Trials, Long-term Outcomes; Safety and Complications; COMBINED THERAPY OF TTM WITH OTHER NEUROPROTECTANTS; Multiple Mechanisms: Erythropoietin (EPO); Anti-oxidant; Anesthetic Gas Xenon; Trophic Factors; Anticonvulsants; Stem Cell Transfusion; CONCLUDING REMARKS; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGMENT; ABBREVIATIONS; REFERENCES; Development of A "Theranostic Nano-Bullet" for Tinnitus: A Systems Neuroscience Approach for Receptor Targeting, Molecular Imaging, and Drug Delivery.
|
| 505 |
8 |
|
|a Anthony T. Cacace*, Aaron K. Apawu, Stephanie M. Curley, James Castracane, Magnus Bergkvist, Angela R. Dixon and Avril Genene HoltINTRODUCTION; Multifunctional Carriers: Detection, Targeting, and Treatment; Molecular Profiling and Biomarkers Associated with Tinnitus: Gene Expression Experiments to Target Pathologic Neural Activity; Attenuating Tinnitus based on Manganese Enhanced Magnetic Resonance Imaging (MEMRI) and Molecular Identification of Protein Targets; BACKGROUND; Models and Theories of Tinnitus; Roadmap to a Cure; The Urgent Need for Development of Pharmacological Treatments.
|
| 500 |
|
|
|a THE ROLE OF DEXMEDETOMIDINE ON NEUROPROTECTION.
|
| 650 |
|
0 |
|a Biopharmaceutics.
|
| 650 |
|
0 |
|a Drugs
|x Design.
|
| 650 |
|
0 |
|a Medical innovations.
|
| 650 |
|
7 |
|a Biopharmaceutics
|2 fast
|
| 650 |
|
7 |
|a Drugs
|x Design
|2 fast
|
| 650 |
|
7 |
|a Medical innovations
|2 fast
|
| 758 |
|
|
|i has work:
|a CNS and neurological disorders Volume 2 Frontiers in clinical drug research (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCFBwc8f6WpYTjF8Kw8qDC3
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
| 776 |
0 |
8 |
|i Print version:
|a Atta-ur-Rahman.
|t Frontiers in Clinical Drug Research - CNS and Neurological Disorders: Volume 6.
|d Sharjah : Bentham Science Publishers, ©2018
|
| 830 |
|
0 |
|a Frontiers in Clinical Drug Research - CNS and Neurological Disorders Ser.
|
| 856 |
4 |
0 |
|u https://ebookcentral.proquest.com/lib/holycrosscollege-ebooks/detail.action?docID=5553428
|y Click for online access
|
| 880 |
8 |
|
|6 505-01/(S
|a Issues Related to BBB Transport with NPsIn-vitro and In Vivo Experiments; In-Vivo Transport of Nanocarriers Across Brain Barriers; SUMMARY; CONCLUDING REMARKS; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGMENT; ABBREVATIONS; REFERENCES; Dexmedetomidine: From Basic Science to Clinical Application of Brain Protection; Zhaosheng Jin1,#, Ka Chun Suen1,#, Azeem Alam1,#, Zac Hana1,#, Dongxin Wang2 and Daqing Ma1,*; INTRODUCTION; PHARMACOLOGY OF DEXMEDETOMIDINE; α2-adrenoreceptors; α2-subreceptors; Distribution; Pharmacokinetics; Distribution; Metabolism; Elimination; Considerations.
|
| 903 |
|
|
|a EBC-AC
|
| 994 |
|
|
|a 92
|b HCD
|